A novel GCGR/GLP-1R dual-agonist TB001 ameliorates kidney fibrosis via inhibiting PERK-mediated endoplasmic reticulum stress pathway
This study demonstrated that TB001, a novel GCGR/GLP-1R co-agonist, effectively attenuates renal fibrosis in pre-clinical models, potentially through the inhibition of PERK-mediated ER stress in tubular cells.
Authors
- Xianxing Jiang (ORCID: https://orcid.org/0000-0002-7508-2368)
- Linjie Peng (ORCID: https://orcid.org/0000-0003-1400-4611)
- Ruobing Li (ORCID: https://orcid.org/0000-0002-5858-9327)
- Qihao Li (ORCID: https://orcid.org/0000-0002-1124-1999)
- Jianliang Min
- Shuangjin Yu
- Guodong Chen (ORCID: https://orcid.org/0000-0001-7671-6281)
- Chang Wang (ORCID: https://orcid.org/0000-0001-8262-7429)
- Longhui Qiu
- Weijie Lai
Institutions
- Sun Yat-sen University (CN)
- Jiaying University (CN)
- Southern University of Science and Technology (CN)
- China International Science and Technology Cooperation (CN)
- Key Laboratory of Guangdong Province (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1665860
- Primary Topic
- Endoplasmic Reticulum Stress and Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- Natural Science Foundation of Guangdong Province